SEC Form 4 · accession 0001209191-17-029193
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael F. Pehl
Officer — See remarks
Period of report
May 1, 2017
Accepted (ET)
May 2, 2017 · 4:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $124.06 | May 1, 2017 | A | 9,391 | A | — | May 1, 2027 | Common Stock | 9,391 | 9,391 | D |
| Restricted Stock UnitF4,F3 | — | May 1, 2017 | A | 4,749 | A | — | — | Common Stock | 4,749 | 4,749 | D |
Explanation of responses
- F1Option is immediately exercisable and will vest in four equal annual installments commencing on May 1, 2018.
- F2The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015).
- F3Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
- F4The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020. Vested shares will be delivered to the reporting person on the vesting date.
Remarks
President, Hematology & Oncology